In "Inside the Be Well Trials: Design, Population, and Patient Selection," the panel walks through why the Be Well trials ...

In "Cross-Trial Vitiligo Data: What Payers Can and Can't Compare," the panel compares cross-trial data directly and discusses ...

This episode, "How Bepirovirsen Targets the Hepatitis B Viral Lifecycle," features the panel debating how much of this ...

In "Counseling Vitiligo Patients on Time to Repigmentation," Dr. Desai and Dr. Lal discuss how to counsel patients through ...

The randomized controlled period (RCP) in the phase 3 MINT trial of inebilizumab for myasthenia gravis (MG) wasn't reported ...

Switching Medicare Advantage (MA) plans is increasingly common among MA enrollees, especially those dually eligible for ...

AJMC: Your study found that emphysema affecting at least 20% of the lung on CT was consistently associated with differences ...

From a health system perspective, Martyn suggested that broader formulary access to finerenone makes sense as long as patient ...

The One Big Beautiful Bill Act restructures Medicaid coverage in ways that have a direct impact on oncology programs. This ...

CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status ...

Patients with ≥5 impaired domains experienced markedly worse outcomes versus none, including >2-fold higher mortality and ...